Crossmark Global Holdings Inc. lowered its position in Baxter International Inc (NYSE:BAX) by 23.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 51,133 shares of the medical instruments supplier’s stock after selling 15,509 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Baxter International were worth $4,276,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Riggs Asset Managment Co. Inc. purchased a new stake in shares of Baxter International in the fourth quarter valued at $25,000. 1 North Wealth Services LLC purchased a new stake in shares of Baxter International in the third quarter valued at $27,000. Savior LLC purchased a new position in Baxter International in the 4th quarter worth about $37,000. Manchester Financial Inc. purchased a new position in Baxter International in the 4th quarter worth about $45,000. Finally, TRUE Private Wealth Advisors purchased a new position in Baxter International in the 4th quarter worth about $46,000. 82.61% of the stock is currently owned by institutional investors and hedge funds.
BAX stock opened at $93.14 on Friday. The company has a market capitalization of $47.26 billion, a PE ratio of 28.66, a P/E/G ratio of 2.16 and a beta of 0.96. Baxter International Inc has a 12 month low of $72.42 and a 12 month high of $95.00. The firm’s 50-day moving average is $88.60 and its 200 day moving average is $85.45. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.78 and a quick ratio of 2.10.
In other Baxter International news, Director John D. Forsyth sold 1,500 shares of the stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $83.64, for a total transaction of $125,460.00. Following the transaction, the director now directly owns 30,078 shares in the company, valued at approximately $2,515,723.92. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.70% of the stock is owned by corporate insiders.
Several research analysts recently commented on the stock. UBS Group reaffirmed a “buy” rating and issued a $102.00 price target on shares of Baxter International in a research note on Monday, January 13th. Wells Fargo & Co raised their price target on shares of Baxter International from $100.00 to $102.00 and gave the stock an “overweight” rating in a research note on Friday. Evercore ISI raised shares of Baxter International from an “in-line” rating to an “outperform” rating and raised their price target for the stock from $80.00 to $94.00 in a research note on Thursday, January 2nd. Deutsche Bank assumed coverage on shares of Baxter International in a research note on Monday, October 21st. They issued a “buy” rating and a $109.00 price target on the stock. Finally, Cfra raised their price target on shares of Baxter International from $87.00 to $93.00 and gave the stock a “hold” rating in a research note on Thursday, February 6th. Six equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Baxter International presently has a consensus rating of “Buy” and a consensus price target of $93.50.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Read More: What is a stock split?
Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.